Literature DB >> 1999537

Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients.

G Elgart1, P Stover, K Larson, C Sutter, S Scheibner, B Davis, J Bass.   

Abstract

The mainstay of therapy for pyoderma gangrenosum has been corticosteroids, but many patients respond poorly. During the past 2 years we have treated seven patients who had pyoderma gangrenosum with cyclosporine after their condition proved resistant to conventional therapy. No evidence of permanent toxicity from cyclosporine was detected and treatment with other immunosuppressive agents was discontinued in five of seven cases. Tuberculosis was reactivated in one patient. Three patients had a remission, three had an intermediate response, and one did not respond. These results indicate that cyclosporine is useful in the treatment of patients with refractory pyoderma gangrenosum and suggest an immune mechanism in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1999537     DOI: 10.1016/0190-9622(91)70016-u

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  3 in total

Review 1.  Unusual causes of cutaneous ulceration.

Authors:  Jaymie Panuncialman; Vincent Falanga
Journal:  Surg Clin North Am       Date:  2010-12       Impact factor: 2.741

Review 2.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

3.  Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial.

Authors:  Anthony D Ormerod; Kim S Thomas; Fiona E Craig; Eleanor Mitchell; Nicola Greenlaw; John Norrie; James M Mason; Shernaz Walton; Graham A Johnston; Hywel C Williams
Journal:  BMJ       Date:  2015-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.